BIOENGINEERED
2026, VOL. 17, NO. 1, 2728903
https://doi.org/10.1080/21655979.2026.2728903

Taylor & Francis
by informa

OPEN ACCESS Check for updates

Statement of Retraction: LncRNA SNHG10 suppresses the development of doxorubicin resistance by downregulating miR-302b in triple-negative breast cancer

We, the Editors and Publisher of the journal *Bioengineered*, have retracted the following article from publication.

Aini, S., Bolati, S., Ding, W., Liu, S., Su, P., Aili, S., Naman, Y., & Xuekelaiti, K. (2022). LncRNA SNHG10 suppresses the development of doxorubicin resistance by downregulating miR-302b in triple-negative breast cancer. *Bioengineered*, 13(5), 11430–11439. https://doi.org/10.1080/21655979.2022.2063592

Since publication, significant concerns have been raised about the integrity of the data and reported results in the article.

When approached for an explanation, the authors did not respond to our queries and so these serious concerns remain unaddressed.

As verifying the validity of published work is core to the integrity of the scholarly record, we are therefore retracting the article. The authors have been informed of this decision.

We have been informed in our decision-making by our policy on publishing ethics and integrity and COPE guidelines.

The retracted article will remain online to maintain the scholarly record and will be digitally watermarked on each page as 'Retracted'.

© 2026 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.